Cancer cells can develop resistance to PARPi through multiple coping mechanisms such as by the restoration of the HR pathway, reversion mutations leading to reactivation of BRCA1/2, upregulation of alternative DNA repair pathways, modulation of PARP activity, or by upregulation of drug efflux transporters (9). This evidence concerns the gene PARP1 and cancer.